Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease

A randomized, double blind, placebo controlled withdrawal trial

Elio Scarpini, Giuseppe Bruno, Giuseppe Zappalà, Marina Adami, Ute Richarz, Maren Gaudig, Adam Jacobs, Barbara Schäuble

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalJournal of Alzheimer's Disease
Volume26
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Galantamine
Alzheimer Disease
Placebos
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • ADAS-cog
  • Alzheimer's disease therapy
  • cognitive
  • galantamine
  • long-term treatment
  • withdrawal design

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease : A randomized, double blind, placebo controlled withdrawal trial. / Scarpini, Elio; Bruno, Giuseppe; Zappalà, Giuseppe; Adami, Marina; Richarz, Ute; Gaudig, Maren; Jacobs, Adam; Schäuble, Barbara.

In: Journal of Alzheimer's Disease, Vol. 26, No. 2, 2011, p. 211-220.

Research output: Contribution to journalArticle

Scarpini, Elio ; Bruno, Giuseppe ; Zappalà, Giuseppe ; Adami, Marina ; Richarz, Ute ; Gaudig, Maren ; Jacobs, Adam ; Schäuble, Barbara. / Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease : A randomized, double blind, placebo controlled withdrawal trial. In: Journal of Alzheimer's Disease. 2011 ; Vol. 26, No. 2. pp. 211-220.
@article{b217d9269470488dbaa38f9fa9d52447,
title = "Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease: A randomized, double blind, placebo controlled withdrawal trial",
abstract = "Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of",
keywords = "ADAS-cog, Alzheimer's disease therapy, cognitive, galantamine, long-term treatment, withdrawal design",
author = "Elio Scarpini and Giuseppe Bruno and Giuseppe Zappal{\`a} and Marina Adami and Ute Richarz and Maren Gaudig and Adam Jacobs and Barbara Sch{\"a}uble",
year = "2011",
doi = "10.3233/JAD-2011-110134",
language = "English",
volume = "26",
pages = "211--220",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease

T2 - A randomized, double blind, placebo controlled withdrawal trial

AU - Scarpini, Elio

AU - Bruno, Giuseppe

AU - Zappalà, Giuseppe

AU - Adami, Marina

AU - Richarz, Ute

AU - Gaudig, Maren

AU - Jacobs, Adam

AU - Schäuble, Barbara

PY - 2011

Y1 - 2011

N2 - Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of

AB - Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of

KW - ADAS-cog

KW - Alzheimer's disease therapy

KW - cognitive

KW - galantamine

KW - long-term treatment

KW - withdrawal design

UR - http://www.scopus.com/inward/record.url?scp=80052793008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052793008&partnerID=8YFLogxK

U2 - 10.3233/JAD-2011-110134

DO - 10.3233/JAD-2011-110134

M3 - Article

VL - 26

SP - 211

EP - 220

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -